Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Astera Cancer Care

Neither a doctor nor a teaching hospital

Research payments

$719,146

127 payments

Through program year 2025, Astera Cancer Care is reported as receiving $719,146 in research payments, across 127 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $99,444 18
2024 Research $289,312 78
2023 Research $151,123 19
2022 Research $115,005 7
2021 Research $28,010 4
2020 Research $36,253 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Amgen Inc. $211,141 11 payments
  2. AstraZeneca Pharmaceuticals LP $108,119 7 payments
  3. Novartis Pharmaceuticals Corporation $99,408 6 payments
  4. Celgene Corporation $69,628 7 payments
  5. Epizyme, Inc., $66,267 17 payments
  6. Exelixis Inc. $63,937 14 payments
  7. Eli Lilly and Company $34,364 8 payments
  8. E.R. Squibb & Sons, L.L.C. $22,236 6 payments
  9. AbbVie, Inc. $20,913 2 payments
  10. Novocure Inc. $17,699 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. P3 1L SCLC Maintenance $136,779 4 payments
  2. A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced Metastatic Solid Tumours $71,619 4 payments
  3. A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma $60,689 12 payments
  4. Epik-B4: A Phase II, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (Byl719) in Combination With Fulvestrant in Participant $58,038 1 payment
  5. A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors $45,403 5 payments
  6. An Open-Label, Multi-Center, Phase II Platform Study Evaluating the Efficacy and Safety of Nis793 and Other New Investigational Drug Combinations With Standard of Care (Soc) Anti-Cancer Therapy for the Second Line Treatment of Metastatic Colorectal Cancer $37,007 2 payments
  7. A Phase 2 Study of Lisocabtagene Maraleucel (Jcar0 $36,253 1 payment
  8. AMG 193 Combo with IDE397 MAT2A $34,701 3 payments
  9. A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) $20,913 2 payments
  10. Phase III RRMM: 480Vd vs PVd (SUCCESSOR 1) - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH R $20,631 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record